These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15961420)

  • 1. Modulation of calcium currents is eliminated after cleavage of a strategic component of the mammalian secretory apparatus.
    Silinsky EM
    J Physiol; 2005 Aug; 566(Pt 3):681-8. PubMed ID: 15961420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine decreases both presynaptic calcium currents and neurotransmitter release at the mouse neuromuscular junction.
    Silinsky EM
    J Physiol; 2004 Jul; 558(Pt 2):389-401. PubMed ID: 15146054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective disruption of the mammalian secretory apparatus enhances or eliminates calcium current modulation in nerve endings.
    Silinsky EM
    Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6427-32. PubMed ID: 18420824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Ca(2+)-dependent and Ca(2+)-independent miniature endplate potentials by phorbol ester and adenosine in frog.
    Searl TJ; Silinsky EM
    Br J Pharmacol; 2005 Aug; 145(7):954-62. PubMed ID: 15880138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gbetagamma acts at the C terminus of SNAP-25 to mediate presynaptic inhibition.
    Gerachshenko T; Blackmer T; Yoon EJ; Bartleson C; Hamm HE; Alford S
    Nat Neurosci; 2005 May; 8(5):597-605. PubMed ID: 15834421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum A toxin and tetanus toxin do not affect presynaptic membrane currents in mammalian motor nerve endings.
    Dreyer F; Mallart A; Brigant JL
    Brain Res; 1983 Jul; 270(2):373-5. PubMed ID: 6309330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue.
    Kalandakanond S; Coffield JA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):749-55. PubMed ID: 11181902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of calcium-dependent and -independent acetylcholine release from motor nerve endings.
    Searl TJ; Silinsky EM
    J Mol Neurosci; 2006; 30(1-2):215-8. PubMed ID: 17192679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of SNARE proteins and synaptotagmin I in synaptic transmission: studies at the Drosophila neuromuscular synapse.
    Kidokoro Y
    Neurosignals; 2003; 12(1):13-30. PubMed ID: 12624525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the t-SNARE SNAP-25 in action potential-dependent calcium signaling and expression in GABAergic and glutamatergic neurons.
    Tafoya LC; Shuttleworth CW; Yanagawa Y; Obata K; Wilson MC
    BMC Neurosci; 2008 Oct; 9():105. PubMed ID: 18959796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct kinetic changes in neurotransmitter release after SNARE protein cleavage.
    Sakaba T; Stein A; Jahn R; Neher E
    Science; 2005 Jul; 309(5733):491-4. PubMed ID: 16020741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of botulinum A toxin and tetanus toxin on the transmitter releasing process at the mammalian neuromuscular junction.
    Dreyer F; Schmitt A
    Neurosci Lett; 1981 Nov; 26(3):307-11. PubMed ID: 6119657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of SNARE protein expression in beta cell lines and pancreatic islets.
    Wheeler MB; Sheu L; Ghai M; Bouquillon A; Grondin G; Weller U; Beaudoin AR; Bennett MK; Trimble WS; Gaisano HY
    Endocrinology; 1996 Apr; 137(4):1340-8. PubMed ID: 8625909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vecuronium suppresses transmission at the rat phrenic neuromuscular junction by inhibiting presynaptic L-type calcium channels.
    Ji F; Han J; Liu B; Wang H; Shen G; Tao J
    Neurosci Lett; 2013 Jan; 533():1-6. PubMed ID: 23200725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targets of botulinum toxin at the mammalian neuromuscular junction.
    Whelchel DD; Brehmer TM; Brooks PM; Darragh N; Coffield JA
    Mov Disord; 2004 Mar; 19 Suppl 8():S7-S16. PubMed ID: 15027049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-bungarotoxin-induced depletion of synaptic vesicles at the mammalian neuromuscular junction.
    Prasarnpun S; Walsh J; Harris JB
    Neuropharmacology; 2004 Aug; 47(2):304-14. PubMed ID: 15223309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective adenosine antagonist (8-cyclopentyl-1,3-dipropylxanthine) eliminates both neuromuscular depression and the action of exogenous adenosine by an effect on A1 receptors.
    Redman RS; Silinsky EM
    Mol Pharmacol; 1993 Oct; 44(4):835-40. PubMed ID: 8232234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of purines on calcium-independent acetylcholine release at the mouse neuromuscular junction.
    Veggetti M; Muchnik S; Losavio A
    Neuroscience; 2008 Jul; 154(4):1324-36. PubMed ID: 18534762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a vertebrate neuromuscular junction that demonstrates selective resistance to botulinum toxin.
    Coffield JA; Bakry NM; Maksymowych AB; Simpson LL
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1509-16. PubMed ID: 10336546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of SNARE protein binding and regulation of Cav2 channels by phosphorylation of the synaptic protein interaction site.
    Yokoyama CT; Myers SJ; Fu J; Mockus SM; Scheuer T; Catterall WA
    Mol Cell Neurosci; 2005 Jan; 28(1):1-17. PubMed ID: 15607937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.